10-Q: Propanc Biopharma Reports Q2 2025 Results: Losses Continue Amid Reverse Stock Split

Sentiment:

Quarterly Report 14 February 2025 1:19 PM

Propanc Biopharma reports ongoing losses for the quarter ended December 31, 2024, while implementing a reverse stock split to address listing requirements.

Delay expectedOutstanding convertible notes for total principal amount of $167,200 with maturity dates between April 2024 and December 2024 are currently in default as of December 31, 2024.

Capital raiseThe company is seeking additional funding through debt and/or equity financing.The company has filed an S-1 registration statement for an underwritten offering of up to $15 million of equity, equity derivatives, and equity linked instruments.

Worse than expectedThe company reported a net loss of $784,493 for the six months ended December 31, 2024, indicating continued financial challenges.The company had no revenue for the six months ended December 31, 2024, highlighting its reliance on external funding.The company's auditor has issued a going concern qualification, raising doubts about its ability to continue operating.

Summary

Propanc Biopharma, a development-stage healthcare company focused on cancer treatments, reported its financial results for the quarter and six months ended December 31, 2024.
The company continues to experience losses, with a net loss of $784,493 for the six-month period and $430,183 for the quarter.
There were no revenues generated during these periods as the company is still in the research and development phase.
Operating expenses decreased due to cost-cutting measures, but the company's ability to continue as a going concern is still in doubt.
A reverse stock split at a ratio of 1:60,000 became effective on January 29, 2025, to address listing requirements.
The company is seeking additional funding through debt and/or equity financing to continue operations.

Sentiment

Score: 3

Explanation: The document presents a negative outlook due to ongoing losses, a going concern qualification, and reliance on external funding. While cost-cutting measures and patent allowance are positive, they are overshadowed by the financial challenges.

Positives

Administration expenses decreased by approximately $338,000 for the six months ended December 31, 2024, compared to the same period in 2023, indicating cost-cutting efforts.
Research and development expenses decreased by approximately $14,000 for the six months ended December 31, 2024, compared to the same period in 2023.
The company received allowance for its proenzyme composition patent from the Canadian Intellectual Property Office (CIPO) on August 14, 2024.

Negatives

The company reported a net loss of $784,493 for the six months ended December 31, 2024.
The company had no revenue for the six months ended December 31, 2024.
The company has a working capital deficit, stockholders deficit and accumulated deficit of $4,136,980, $4,158,759, and $67,482,713, respectively.
The company's auditor has issued a going concern qualification.
The company is in default under certain loan agreements.

Risks

The company's ability to continue as a going concern is dependent on obtaining adequate financing.
The company is subject to litigation and claims arising in the ordinary course of business.
The company is dependent on key personnel, including James Nathanielsz.
The company's lead product candidate, PRP, is still in the preclinical phase of development.
The company is subject to the risk of not being able to obtain regulatory approval for its products.
The company is subject to the risk of competition from other companies in the pharmaceutical industry.

Future Outlook

The company intends to continue its research and development efforts and seek additional funding through debt and/or equity financing. The company is also pursuing a public offering and uplisting to the Nasdaq Capital Market.

Industry Context

The company operates in the competitive biopharmaceutical industry, focusing on developing novel cancer treatments. The industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition.

Comparison to Industry Standards

It is difficult to compare Propanc Biopharma's results to industry standards due to its early stage of development and lack of revenue.
Comparable companies in the biopharmaceutical industry typically have significant research and development expenses and may rely on partnerships or licensing agreements to generate revenue.
Many companies in the biopharmaceutical industry are also pursuing novel cancer treatments, including pro-enzyme formulations.

Related Party Transactions

The company has conducted transactions with its directors and entities related to such directors.
The company owed its former director a total of $27,491 and $45,754 related to expenses paid on behalf of the Company and money loaned to the Company, respectively.
The company leases its principal executive offices from North Horizon Pty Ltd., a related party.
An institutional investor affiliated with one of the company's directors, Josef Zelinger, loaned the company an aggregate of $71,629.
The company entered into a loan agreement with an institutional investor affiliated with one of its directors, Josef Zelinger, for an aggregate principal amount of $153,256 USD.

Stakeholder Impact

Shareholders may experience dilution due to potential equity financing.
Employees may be affected by cost-cutting measures.
The company's ability to develop and commercialize its products may impact patients with cancer.
Creditors may be at risk due to the company's financial difficulties.

Next Steps

The company intends to continue its research and development efforts.
The company intends to seek additional funding through debt and/or equity financing.
The company intends to pursue a public offering and uplisting to the Nasdaq Capital Market.

Key Dates

Date	Description
2007-10-15	Propanc PTY LTD was originally formed in Melbourne, Victoria, Australia.
2010-11-23	Propanc Health Group Corporation was incorporated in the State of Delaware.
2011-01	Propanc Health Group Corporation acquired all of the outstanding shares of Propanc PTY LTD.
2016-07-22	Propanc (UK) Limited was formed under the laws of England and Wales.
2017-04-20	The Company changed its name to Propanc Biopharma, Inc.
2019-05-14	The Company entered into an Amended and Restated Employment Agreement with Mr. Nathanielsz.
2020-07	A world-first patent was granted in Australia for the cancer treatment method patent family.
2022-05-04	The Company entered in a three -year lease agreement with North Horizon Pty Ltd.
2022-07-27	The Company entered into a two-year research agreement with the University of Jan.
2023-07-05	The Company and an institutional investor affiliated with one of our directors, Josef Zelinger, entered into a letter agreement, pursuant to which such investor loaned the Company an aggregate of $230,000 AUD.
2024-08-07	The Company received written consent in lieu of a meeting by the holders of a majority of the voting power of the Companys outstanding capital stock as of August 7, 2024 and the Companys Board of Directors approving such actions as are necessary for the Company to proceed to, and the Company accordingly intends to, effectuate and execute a reverse stock split of the Companys issued and outstanding shares of common stock at a ratio of one post-split share per sixty thousand pre-split shares (1:60,000) (the Reverse Stock Split).
2024-08-14	Allowance for the Companys proenzyme composition patent was received from the Canadian Intellectual Property Office (CIPO).
2024-10-30	We filed an S-1 registration statement with the Securities and Exchange Commission for an underwritten offering that reflects the proposed reverse split of the outstanding Common Stock and treasury stock of the Company at an assumed 1for60,000 ratio, which is anticipated to occur prior to the closing of the offering.
2025-01-29	The Reverse Stock Split became effective.

Keywords

Propanc Biopharma, financial results, net loss, reverse stock split, PRP, cancer treatment, research and development, going concern, convertible debt, loan default

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.